• PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment. [ Time Frame: Day 1 to Day 23 ]
  Maximum plasma concentration (Cmax)
• PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment. [ Time Frame: Day 1 to Day 23 ]
  Area under the concentration-time curve (AUC) from time zero up to the last time point with a quantifiable concentration (AUC0-last)
• PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment. [ Time Frame: Day 1 to Day 23 ]
  AUC up to time infinity, with extrapolation of the terminal phase (AUC0-inf)

• PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment. [ Time Frame: Day 1 to Day 23 ]
  Terminal half-life (t1/2)
• PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment. [ Time Frame: Day 1 to Day 23 ]
  Time to occurrence of Cmax (tmax)
• PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment. [ Time Frame: Day 1 to Day 23 ]
  Apparent total clearance of drug after oral administration (CL/F)
• PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment. [ Time Frame: Day 1 to Day 23 ]
  Apparent volume of distribution during terminal phase (Vz/F)
• The following secondary PK parameter will be calculated for rucaparib. [ Time Frame: Day 1 to Day 23 ]
  Trough plasma concentration (Cmin)
• Incidence of Adverse Events [Safety and Tolerability] [ Time Frame: From Day 1 to last patient visit in Part II (approximately 2 years) ]
• Incidence of clinical laboratory abnormalities [Safety and Tolerability] [ Time Frame: From Day 1 to last patient visit in Part II (approximately 2 years) ]
• Incidence of dose modifications [Safety and Tolerability] [ Time Frame: From Day 1 to last patient visit in Part II (approximately 2 years) ]

This is a Phase 1, open-label, drug-drug-interaction (DDI) study in patients with advanced solid tumor. In Part I, the effects of rucaparib (600 mg twice daily [BID]) on the PK of oral rosuvastatin (Arm A) and the combined oral contraceptives (ethinylestradiol and levonorgestrel; Arm B) will be assessed.

Part I: patients will receive single oral doses of rosuvastatin or oral contraceptives (according to assigned arm) on Day 1 and Day 19. Continuous treatment with rucaparib at 600 mg BID will commence on Day 5 and continue until the end of Part I (Day 23).

Part II (optional): treatment with rucaparib in 28-day cycles may continue (at the discretion of the Investigator) until progression of disease, unacceptable toxicity, or other reason for discontinuation.

• Drug: Rucaparib
  Rucaparib 600 mg BID commencing on Day 5 until Day 23.
  Other Name: Rubraca
• Drug: Rosuvastatin
  Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
  Other Name: Crestor
• Drug: Oral Contraceptives
  Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.

• Arm A - rucaparib and oral rosuvastatin
  Interventions:

  • Drug: Rucaparib
  • Drug: Rosuvastatin
• Arm B - rucaparib and oral contraceptives
  Interventions:

  • Drug: Rucaparib
  • Drug: Oral Contraceptives

Inclusion Criteria (All patients):

• Willing to sign the ICF and to comply with the study restrictions
• Body mass index (BMI) 18.0 to 35.0 kg/m2
• Histologically or cytologically confirmed advanced solid tumor
• Patients who, in the opinion of the Investigator, could potentially benefit from treatment with rucaparib
• ECOG performance status less than or equal to 1
• Adequate organ function

Inclusion Criteria (Arm A):

- Male or female patients ≥ 18 years of age

Inclusion Criteria (Arm B):

- Female patients ≥ 18 years of age

Exclusion Criteria (All patients):

• Specific cancer treatments within 14 days prior to Day 1
• Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, acute coronary syndrome, cardiac angioplasty, stenting, or poorly controlled hypertension within the last 3 months prior to screening
• Pre-existing duodenal stent, recent or existing bowel obstruction
• Untreated or symptomatic central nervous system (CNS) metastases. Patients with treated asymptomatic CNS metastases are eligible
• Known HIV or AIDS-related illness, acute or history of chronic hepatitis B or C
• Female patients who are pregnant or breastfeeding
• Participation in another investigational drug trial within 30 days prior to Day 1 or exposure to more than 3 new investigational agents within 12 months prior to Day 1
• Presence of active infection requiring antibiotics
• Active second malignancy
• History of drug abuse (including alcohol)

Exclusion Criteria (Arm A):

• Current use of rosuvastatin or any other statin
• History of hypersensitivity to rosuvastatin
• Current, or history of, clinically significant myopathy

Exclusion Criteria (Arm B):

• Current use of any 1 of the contraceptive drugs or previous contraceptive implants or depot injections, which may still be clinically effective
• History of hypersensitivity to ethinylestradiol or levonorgestrel